Tet methylcytosine dioxygenase 2

So they exist in all of us in the normal state.

But in patients who develop this background of clonal hematopoiesis, which we identify through chip mutations, the most common one in this disease is TET2.

It often co-occurs with ASXL1 and other splicing site mutations and transcription factors.

They develop these mutations, and then the plasmacytic dendritic cells harboring these mutations seem to relocate onto the skin.

Yeah.

So there are many papers showing the most common genetic mutations, molecular mutations that are seen in BPDCN.

The ones that I mentioned already, the TET2 mutations, ASXL1, and things like SRSF2 are some of the more common ones.

Back to the topic of AML and other leukemias, though, one thing to note about BPDCN is that this disease can actually co-occur with patients who have underlying other myeloid malignancies.

Mutations in the epigenetic regulator genes that control which other genes are switched on or off.

And there we go, the TET2.

And then we break it down to that.

Clinical translation.

About 90% of the age-shifted genes they tracked in those nerve cells returned toward youthful levels.

Two cleanup enzymes turned out to be the janitors, TET1 and TET2.

They stripped off some of those methylation marks.

When the team silenced TET1 or TET2, the magic mostly vanished.

They were recruiting a demolition and restore crew for the epigenome.

A later mouse study followed animals for a year.

Definitely.

The OSK factors recruit specific enzymes, primarily TET1 and TET2.

These enzymes actively hunt down and chemically cleave the aberrant methyl tags off the DNA.

If you genetically knock out TET1 and TET2, the reprogramming fails entirely.

So the cell sheds the static, regains its youthful structure, but crucially retains just enough memory to know it's a retinal cell.

It is a breathtaking biochemical tightrope walk.

Somatic mutations are also incorporated into the model.

The review discusses clonal hematopoiesis of indeterminate potential in which age-acquired mutations in genes such as DNMT3A, TET2, and ASXL1 promote clonal expansion.

Rather than dismissing these processes, the framework treats them as potentially important accelerating cofactors alongside largely mutation-independent DDR dysregulation.

To organize these mechanisms, the review identifies 16 candidate tumor suppressor negative regulator axes across three evidence tiers.